Skip to main content
Equibles

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Position in ARDX — Ardelyx, Inc.

CIK 861177 NEW YORK, NY
Back to ARDX Full portfolio

Position in ARDX

as of Mar 31, 2026 · filed May 13, 2026
Position Value
$2,639,634
+$125,467 QoQ
Shares Held
440,674
+2.2% QoQ
Ownership
0.178%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2020
19 quarters on record
Voting authority Sole 50% Shared 0% None 50%

Common Shares in ARDX Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,287,037,771 across 211 Biotechnology names. ARDX ranks #93 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 3,057,396 $1,365,249,602
2 REGN
Regeneron Pharmaceuticals, Inc.
 723,621 $559,098,523
3 ALNY
Alnylam Pharmaceuticals, Inc.
 677,519 $224,170,706
4 INSM
INSMED Inc
 1,215,025 $198,680,883
5 RPRX
Royalty Pharma plc
 3,095,766 $148,503,890
6 INCY
Incyte Corp
 1,540,913 $145,030,725
7 IONS
Ionis Pharmaceuticals Inc
 1,475,632 $110,805,201
8 DNLI
Denali Therapeutics Inc.
 4,432,314 $85,100,425

All Filings in ARDX

Export CSV
19 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $2,639,634 440,674
2025-12-31 $2,514,167 431,247
2025-09-30 $2,039,297 370,109
2025-06-30 $2,486,236 634,245
2025-03-31 $2,567,185 522,849
2024-12-31 $2,931,753 578,256
2024-09-30 $3,003,775 435,962
2024-06-30 $3,552,395 479,406
2024-03-31 $2,256,406 309,097
2023-12-31 $1,926,004 310,646
2023-09-30 $1,275,483 312,619
2023-06-30 $605,008 178,469
2023-03-31 $854,864 178,469
2021-09-30 $114,282 86,578
2021-06-30 $656,261 86,578
2021-03-31 $495,176 74,800
2020-12-31 $394,670 61,000
2020-09-30 $264,075 50,300
2020-06-30 $360,988 52,166

Report a Problem

Category
Description
Email (optional, for follow-up)